Skip to main content
. Author manuscript; available in PMC: 2022 Nov 16.
Published in final edited form as: Cancer Res. 2022 May 16;82(10):2019–2030. doi: 10.1158/0008-5472.CAN-21-0871

Figure 2. Loss of EZH2 results in a radiation resistant phenotype in group 3 medulloblastoma.

Figure 2

(A) Western blot (WB) analysis of indicated proteins in EZH2-WT (H3K27me3-proficient) and EZH2-KO (H3K27me3-deficient) group 3 medulloblastoma cells derived from orthotopic tumors that were established using murine Myc-expressing CDKN2C−/−, p53−/− cerebellar GNP. (B-C) MTT assay demonstrating survival in group 3 medulloblastoma cells ((B) clone #51, (C) clone #68). Cells were treated with indicated doses of ionizing radiation (IR) and percentage of viable cells was determined 7d later. (D-E) Colony formation assay demonstrating survival in EZH2-WT and EZH2-KO group 3 medulloblastoma cells ((D) clone #51, (E) clone #68). Cells were treated with indicated doses of ionizing radiation (IR) and survival was assessed by colony formation assay 7d later. (B-E) Data of three independent experiments are shown as mean +/− SD. Paired two-tailed T-test was used for statistical analysis (***p < 0.001; **p < 0.01; *p < 0.05).